Related Experiment Videos
[Effectiveness of a combined live mumps-measles vaccine]
Abstract:
The reactogenic and areactogenic properties of a live combined mumps-measles vaccine (MMV) prepared in primary cultures of Japanese quail embryo cells from attenuated strains of mumps (L-3) and measles (L-16) viruses were under study. The observations involved 648 infants varying in ages from 1 to 3 years, seronegative to measles and mumps viruses, without the history of the disease and vaccinations against these infections or contraindications to vaccinations. The infants were vaccinated with 5 batches of MMV with different portions of the mumps and measles components. The vaccinees and controls (placebo injections) were observed for 30 days postvaccination. The live MMV was shown to be a safe, well tolerated preparation with low reactogenicity and a high antigenic activity.
Insights
A live combined mumps-measles vaccine (MMV) demonstrated safety and effectiveness in infants. This well-tolerated preparation showed low reactogenicity and high antigenic activity in clinical observations.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Live combined mumps-measles vaccine (MMV) development is crucial for pediatric infectious disease prevention.
- Understanding the reactogenic and areactogenic properties of novel vaccine formulations is essential for safety assessment.
Purpose of the Study:
- To evaluate the safety, reactogenicity, and antigenic activity of a live combined mumps-measles vaccine (MMV).
- To assess the efficacy of MMV produced in Japanese quail embryo cell cultures.
Main Methods:
- Clinical observation of 648 infants aged 1-3 years, seronegative for measles and mumps.
- Vaccination with 5 batches of live MMV with varying component ratios.
- 30-day post-vaccination monitoring of vaccinees and placebo controls.
Main Results:
- The live MMV exhibited low reactogenicity and was well-tolerated by infants.
- High antigenic activity was observed, indicating robust immune response.
- The vaccine proved to be a safe preparation.
Conclusions:
- The live combined mumps-measles vaccine (MMV) is a safe and effective option for infant immunization.
- MMV demonstrates favorable reactogenic and antigenic profiles, supporting its clinical use.